This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Alert me on articles by topic

Arch Dermatol. 2004;140:893-894.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hypospadias is a birth defect that affects approximately seven in 1,000 male infants in the United States. In affected infants, the urethral opening is located along the underside of the penis, scrotum, or perineum; the condition usually is corrected by surgery. Hypospadias is classified in order of increasing severity as first, second, or third degree. In 2002, a study in Sweden noted that among male infants born to women who while pregnant had taken loratadine (Claritin®), a nonsedating antihistamine commonly used for seasonal allergies, hypospadias prevalence was twice that of the general population.¹ However, insufficient data were available to determine the severity of the hypospadias cases, and the study did not control for confounding variables (eg, family history of hypospadias or maternal age). In 2003, a prospective study using data from four countries indicated that five of 142 pregnancies in women exposed to loratadine resulted in infants with major malformations, . . . [Full Text of this Article]

Reported by:


Editorial Note:

Acknowledgments